CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation
PHILADELPHIA, PA / ACCESS Newswire / July 28, 2026 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR).
On July 27, 2026, the U.S. Food and Drug Administration ("FDA") released briefing materials concerning Capricor's application for FDA approval of deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.
According to Reuters, "FDA staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics' cell therapy for a heart condition related to Duchenne muscular dystrophy . . .." Reuters further reported that "[t]he briefing documents . . . mention the effectiveness and risk-benefit profile of the experimental therapy, deramiocel, to be discussed at the FDA's external advisers' meeting on Wednesday." Additionally, Reuters reported that "[t]he agency's staff said Capricor changed how it measured the main results after the therapy's late-stage trial ended, calculating arm-function performance as a percentage change instead of the original plan of analyzing scores in a 42-point test."
On this news, Capricor's stock price fell more than 60%, closing at $7.00 per share on July 27, 2026.
Capricor investors who have suffered financial losses are encouraged to complete Kehoe Law Firm's Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for additional information and a free, no-obligation evaluation of potential legal claims.
ABOUT KEHOE LAW FIRM, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.
Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.
This press release may constitute attorney advertising.
SOURCE: Kehoe Law Firm, P.C.